TY - JOUR
T1 - Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope
AU - Omiya, Ryusuke
AU - Buteau, Chantal
AU - Kobayashi, Hiroya
AU - Paya, Carlos V.
AU - Celis, Esteban
PY - 2002/8/15
Y1 - 2002/8/15
N2 - Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.
AB - Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid, organ transplant patients.
UR - http://www.scopus.com/inward/record.url?scp=0037103364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037103364&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.169.4.2172
DO - 10.4049/jimmunol.169.4.2172
M3 - Article
C2 - 12165547
AN - SCOPUS:0037103364
SN - 0022-1767
VL - 169
SP - 2172
EP - 2179
JO - Journal of Immunology
JF - Journal of Immunology
IS - 4
ER -